Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.01
-0.23 (-3.69%)
At close: May 18, 2026, 4:00 PM EDT
6.04
+0.03 (0.50%)
After-hours: May 18, 2026, 7:29 PM EDT

Xeris Biopharma Holdings Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
12.010.55-54.84-62.26-94.66-122.73
Depreciation & Amortization
12.1812.1612.0712.3312.241.88
Stock-Based Compensation
22.0622.3718.3610.7212.1611.38
Other Adjustments
43.91-3.76-1.522.522.08
Change in Receivables
-9.97-10.64-1.22-8.37-13.37-6.24
Changes in Inventories
-14.82-19.29-8.78-14.8-7.47-7.42
Changes in Accounts Payable
0.12-0.07-9.616.96-4.325.53
Changes in Accrued Expenses
10.393.313.65-5.86-11.3812.56
Changes in Other Operating Activities
12.5516.327.1415.771.397.43
Operating Cash Flow
48.5328.63-36.98-47.02-102.89-95.54
Capital Expenditures
-1.01-0.7-0.87-2.26-0.52-1.09
Purchases of Investments
---34.49-43.74--43.02
Proceeds from Sale of Investments
--40.244034.99103.6
Other Investing Activities
-----38.47
Investing Cash Flow
-1.01-0.74.88-634.4697.96
Long-Term Debt Issued
--50-146.21-
Long-Term Debt Repaid
-----43.5-
Net Long-Term Debt Issued (Repaid)
--50-102.72-
Issuance of Common Stock
1622.271.730.5830.8427.84
Repurchase of Common Stock
-19.9-10.88-3.73-1.01-0.47-0.53
Net Common Stock Issued (Repurchased)
-3.8911.39-2-0.4330.3727.3
Other Financing Activities
---11.83-1.19-5.61-0.05
Financing Cash Flow
5.6911.3936.17-1.61127.4727.25
Effect of Exchange Rate Changes on Cash and Cash Equivalents
------0
Net Cash Flow
53.2139.324.07-54.6459.0429.67
Free Cash Flow
47.5227.93-37.85-49.29-103.42-96.62
Free Cash Flow Growth
70.14%-----
FCF Margin
15.09%9.57%-18.64%-30.07%-93.80%-194.84%
Free Cash Flow Per Share
0.270.16-0.26-0.36-0.76-1.22
Levered Free Cash Flow
31.4212.29-1.24-50.12-2-103.84
Unlevered Free Cash Flow
55.3236.63-28.71-31-90.78-96.27
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q